Background-An important determinant of successful cardiac resynchronization therapy for heart failure is the position of the left ventricular (LV) pacing lead. The aim of this study was to analyze the impact of the LV lead position on outcome in patients randomized to cardiac resynchronization-defibrillation in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) study. Methods and Results--The location of the LV lead was assessed by means of coronary venograms and chest x-rays recorded at the time of device implantation. The LV lead location was classified along the short axis into an anterior, lateral, or posterior position and along the long axis into a basal, midventricular, or apical region. The primary end point of MADIT-CRT was heart failure (HF) hospitalization or death, whichever came first. The LV lead position was assessed in 799 patients, (55% patients Ն65 years of age, 26% female, 10% LV ejection fraction Յ25%, 55% ischemic cardiomyopathy, and 71% left bundle-branch block) with a follow-up of 29Ϯ11 months. The extent of cardiac resynchronization therapy benefit was similar for leads in the anterior, lateral, or posterior position (Pϭ0.652). The apical lead location compared with leads located in the nonapical position (basal or midventricular region) was associated with a significantly increased risk for heart failure/death (hazard ratioϭ1.72; 95% confidence interval, 1.09 to 2.71; Pϭ0.019) after adjustment for the clinical covariates. The apical lead position was also associated with an increased risk for death (hazard ratioϭ2.91; 95% confidence interval, 1.42 to 5.97; Pϭ0.004). Conclusion-LV leads positioned in the apical region were associated with an unfavorable outcome, suggesting that this lead location should be avoided in cardiac resynchronization therapy. Clinical Trial Registration-URL: http://clinicaltrials.gov.
C ardiac resynchronization therapy (CRT) is now recognized as a safe and efficient therapeutic strategy for medically refractory congestive heart failure (HF). Implantable CRT devices via synchronized pacing from the right ventricle and left ventricle (LV) can enhance the contractility of the failing heart and thereby alter the natural history of the disease process. 1 Biventricular pacing is associated with an improved quality of life, increased functional capacity, reduction in hospitalization for HF, and increased survival. [1] [2] [3] [4] The Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) study recently showed that CRT combined with an implantable cardioverter-defibrillator device in asymptomatic and mildly symptomatic patients with a reduced LV ejection fraction (LVEF) and a wide QRS complex was associated with a 34% reduction in the risk of HF events or death compared with those with an implantable cardioverter-defibrillator alone. 5
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Unfortunately, a significant proportion of patients do not respond to CRT, 1, 4 adversely affecting the utility and costeffectiveness of this form of device therapy for HF. 6 Although the location of the pacing site along the LV wall and the consequent ventricular synchrony are important determi-nants of clinical outcome, 7, 8 they have not been systematically studied. The influence of the LV pacing site on HF hospitalization and total mortality has not yet been adequately examined in a prospectively study conducted in patients with New York Heart Association class I or II. The present investigation examines the impact of the LV lead position on HF events and mortality in mildly symptomatic patients randomized to the CRT arm of the MADIT-CRT study.
Methods

Study Subjects
The MADIT-CRT trial was a prospective multicenter trial that enrolled subjects from 110 hospital centers. A description of the study design and protocol has been published. 5 Male and female patients Ͼ21 years of age were eligible for the study if they had ischemic cardiomyopathy (New York Heart Association class I or II) or nonischemic cardiomyopathy (class II only). All enrolled patients were in normal sinus rhythm, with an LVEF Յ30% and a QRS duration of Ն130 milliseconds. All eligible subjects met the guideline indications for implantable cardioverter-defibrillator therapy. Of the 1820 patients enrolled in the study, 1089 were randomized to the CRT-defibrillation arm.
Definitions of all clinical variables were outlined before the start of MADIT-CRT. Subjects underwent a detailed clinical and echocardiographic evaluation just before recruitment to the study. All patients provided written informed consent. The trial sponsor, Boston Scientific, was not involved in either data collection or data analysis. The authors take complete responsibility for the veracity of the reported findings.
Follow-Up and End Points
All data of baseline characteristics, including the results of the invasive and noninvasive cardiac evaluations, were collected prospectively in the MADIT-CRT study population. 5 Patients were seen 1 month after the implantation and then subsequently every 3 months until termination of the trial. All patients had a detailed clinical evaluation and device interrogation at each follow-up visit. Patients were followed up in each center, and data concerning all device therapy were obtained at the time of device interrogation and retrieval of stored electrograms.
The primary end point was death resulting from any cause or nonfatal HF, whichever came first. Two separate end-point committees for HF and mortality were used for the adjudication process. 5
LV Lead Location
As a part of the MADIT-CRT protocol, all implanting physicians were asked to perform a preimplantation coronary venous angiogram in at least 2 orthogonal views (left anterior oblique, 20°to 40°, and right anterior oblique, 20°to 40°), store postimplantation fluoroscopic images in the same views, and obtain postprocedural chest x-rays (anteroposterior and lateral views) before discharge. The venous angiogram video recordings and digital chest x-ray images were copied onto a CD-ROM and sent to the core laboratory at the University of Rochester Medical Center. Although physicians were recommended to implant the LV lead in a coronary venous branch along the lateral and posterolateral region, the final lead position was at the implanting physician's discretion. Implanting physicians were advised to place the right ventricular (RV) lead in the apical region for optimizing stability and defibrillation thresholds. Final placement of the RV lead was also adjudicated by the core laboratory.
Detailed evaluation of the preimplantation venogram and postimplantation LV lead images was made to locate the final position of the LV lead. The LV epicardial surface was divided into 15 different segments using the 2-view approach (ie, right and left anterior oblique). 9, 10 The right anterior oblique view, representative of the long axis of the heart, was used to classify the lead position into basal, midventricular, and apical segments ( Figure 1A ). 11 The left anterior oblique view, comparable to the short-axis view of the heart, was used to divide the LV wall into 5 equal parts: anterior, anterolateral, lateral, posterolateral, and posterior ( Figure 1B ). For the analysis, the anterolateral, lateral, and posterolateral segments were grouped together as the lateral wall. The final LV positions were analyzed by using both axis views together; however, for the purpose of simplification, the definitive LV lead locations were classified as positioned in the anterior, lateral, or posterior segment (corresponding with the short-axis view), as well as in the basal, midventricular, or apical segment (corresponding with the long-axis view). 12
Statistical Analysis
Continuous variables are expressed as meanϮSD. Categorical data are summarized as frequencies and percentages. Baseline clinical characteristics were compared between the groups, stratified by LV lead position, with the use of the Wilcoxon rank-sum or Kruskal-Wallis test for continuous variables and 2 (or Fisher exact) test for dichotomous variables as appropriate.
Cumulative death and HF hospitalization probability curves were determined according to the Kaplan-Meier method, with comparisons of cumulative event rates by the log-rank test. Multivariate Cox proportional hazards regression analysis was used to evaluate the impact of LV lead location on the combined end point of HF or mortality, whichever came first. Prespecified variables capturing gender, ischemic status, QRS Ն150 milliseconds, and left bundlebranch block (LBBB) were used in the multivariate model because of their clinical relevance. Additional variables that varied across lead locations in the univariate analysis with a significance of at least 0.10 were assessed with the use of the best subsets regression method. These variables were right bundle-branch block, LVEF, blood urea nitrogen Ͼ25 mg/100 mL, diabetes mellitus, previous smoking, diastolic and systolic blood pressures, and heart rate. LVEF was found to provide additional significant end-point prediction and was included with the 4 prespecified variables in the multivariate model. Adjusted hazard ratios (HRs) with their 95% confidence intervals 
Results
Distribution of LV Lead Location
From the 1089 patients randomized to the CRT arm, 56 (5%) never received a CRT device or withdrew before CRT implantation. Of 1033 CRT implants, 66 (6.4%) patients crossed over to the implantable cardioverter-defibrillator arm after CRT implantation. Of the remaining 967 patients, an additional subset of patients were excluded because of necessary epicardial lead placement (nϭ36), lead revisions (nϭ54) during follow-up, or incompletely transferred data sets (nϭ78). Therefore, a total of 799 were evaluated for final LV lead location. Along the short axis, the LV lead was most commonly located on the lateral wall (nϭ468, 59%) compared with the posterior (nϭ176, 22%) and anterior (nϭ155, 19%) walls. The distribution of the LV lead location along the long axis was as follows: apical segment, nϭ110 (14%); basal, nϭ183 (23%), and midventricular, nϭ506 (63%). The 3 most predominant segmental lead locations were along the lateral-mid (nϭ288), anterior-basal (nϭ95), and posteroapical (nϭ83) segments ( Figure 2 ).
The RV pacing/defibrillation lead was placed in the RV apex in 708 patients (88%). A midseptal RV lead position was chosen by the implanting physician in 62 patients (8%) and the RV outflow-tract position in 29 patients (4%). However, the nonapical RV lead placement was not significantly different between the various LV lead locations.
LV Lead Location and Baseline Clinical Characteristics
The LV lead position was assessed in 799 patients (55% patients Ն65 years of age, 26% female, 10% LVEF Յ25%, 55% ischemic cardiomyopathy, and 71% LBBB) with a follow-up of 29Ϯ11 months. The baseline characteristics of the patients were categorized by LV lead location along the short and longitudinal axes. Table 1 shows the clinical characteristics in the 3 groups divided into anterior, lateral, and posterior walls. There were no significant differences in age, gender, cause of cardiomyopathy, LVEF, QRS width, prevalence of LBBB morphology, or medication use among the 3 groups. Similarly, Table 2 shows the absence of any significant differences in the baseline clinical characteristics categorized by LV lead location in the apical and nonapical (basal and midventricular) segmental positions. Also noteworthy is that the baseline clinical characteristics in the excluded patients were comparable to those with the complete data set used for this analysis.
Clinical Events and LV Lead Location
A total of 116 patients (14.5%) reached primary end points of either HF hospitalization or outpatient HF treatment (nϭ105) or death (nϭ11). Of the 105 patients who developed HF, 18 died of pump failure after they had reached the primary end point. Altogether, a total of 37 patients died during the whole study follow-up. In addition to the 18 patients who died of HF, 7 patients had sudden death, and 10 patients had noncardiac death (stroke, nϭ2; cancer, nϭ7; and hypoglycemia, nϭ1). In 2 patients, the cause of death was undeterminable. No significant differences were noted in clinical outcome, HF, or death between the LV lead positioned along the anterior, lateral, or posterior walls, excluding the apical lead positions (Pϭ0.652; Figure 3A ).
When subdivided by apical and nonapical LV lead location, there were 24 primary end-point events (21.8%) in the apically located leads. Of these, 20 developed HF and 4 died (2 sudden deaths and 2 noncardiac deaths [stroke]). During further follow-up of patients with an apical lead position who had reached the primary end point, 6 additional patients died of HF and another patient had a noncardiac death. The nonapical LV lead location was associated with 92 primary end points (13.3%). A total of 85 patients developed HF, and 7 patients died (3 sudden deaths, 2 noncardiac deaths, and 2 deaths of undeterminable cause). Additionally, 19 patients died after having reached the primary end point (12 of HF, 2 of sudden death, and 5 of noncardiac causes). An apical lead position was associated with a significantly higher HF hospitalization/death rate than leads located in the nonapical position, ie, the midventricular or basal location (21.8% versus 14% and 10%, respectively; Pϭ0.014). Kaplan-Meier estimates of event-free outcome in the apical versus nonapical group are shown in Figure 3B . The increased risk for HF/death in patients with apical lead positions (HRϭ1.64; 95% CIϭ1.05 to 2.58; Pϭ0.03) was observed even after adjustment for the clinical covariates. Table  3 shows the HRs for the primary end point of HF or death, HF only, and death alone comparing the various LV lead positions in the total population. The apical lead position was also associated with an increased risk for death (HRϭ2.91; 95% CIϭ1.42 to 5.97; Pϭ0.004). The highest HR for HF or death of the apical lead position was always observed compared with the basal (anterior, lateral, or posterior) lead position. The effects of the impact of LV lead location in 7 prespecified groups are presented in Figure 4 . Interaction effects between the subgroup and LV lead location were identified in 1 subset: Apical lead location was associated with a significantly worse outcome in patients with an LVEF Ͻ25% (HRϭ4.1; 95% CIϭ1.65 to 9.95) compared with those with an LVEF Ͼ25% (Pϭ0.001). This subgroup interaction, however, should be interpreted with caution in view of the multiple testing involved. An interaction between the LV lead positions in the 2 different axis views (long axis or right anterior oblique and short axis or left anterior oblique) was excluded by Cox multivariate regression analyses.
Further analysis in patient subgroups showed that there was no difference in outcome among patients with anterior, posterior, and lateral lead positions among patients with LBBB (Pϭ0.55), ischemic (Pϭ0.90), and nonischemic (Pϭ0.24) cardiomyopathy. The apical lead position was associated with a significantly worse clinical outcome compared with nonapical lead positions in LBBB (Pϭ0.009) and nonischemic (Pϭ0.03) but not ischemic (Pϭ0.16) cardiomyopathy. Also noteworthy is that the extent of CRT benefit was similar among all lead positions in patients with non-LBBB morphology. Apical lead placement was associated with a worse outcome in men (Pϭ0.007) but not in women (0.52). No gender differences were noted in the extent of CRT benefit from anterior, posterior, or lateral wall lead placement. There was a significant reduction in LV end-diastolic and-systolic volumes and an improvement in LVEF in patients receiving CRT. However, there was no difference in volume reduction or increase in LVEF between the various LV lead positions. Patients with an apical lead position who met the primary end points tended to have less reverse remodeling than those who did not, but the difference was not statistically significant. In a multivariate analysis, the determinants of an unfavorable outcome in patients with an apical lead position were LVEF Ͻ25% (HRϭ8.1; 95% CIϭ2.95 to 22.14; PϽ0.001) and prior history of New York Heart Association class ϾII (HRϭ7.4; 95% CIϭ2.5 to 22.0; PϽ0.001).
Discussion
Although CRT is now an accepted therapeutic modality for patients with HF and conduction disturbances, a significant proportion of patients remain nonresponders. 1 Our study shows that LV lead location may be a significant contributor to this nonresponsiveness and that pacing the apical region of the LV is associated with a worse clinical outcome, including significantly higher mortality rates. Our results also demonstrate that LV lead location along the short axis (ie, anterior, lateral, or posterior wall) does not influence the primary end points of HF hospitalization and all-cause mortality. This is the first study from a randomized clinical trial to examine the impact of LV lead location on clinical outcome in which venous angiography and LV lead position data were collected prospectively and evaluated independently.
Prior work has recommended that targeting the lateral or posterolateral wall by way of either an appropriate coronary sinus branch or surgical (epicardial) placement is a determinant of improved clinical outcomes. 7, 13 This strategy is based on the contention that most patients eligible for CRT usually have a LBBB; typically, the latest activated site of the ventricle is along the lateral or posterolateral wall. 14 Earlier work has also suggested that appropriately positioning the LV lead in the region of greatest electric 8 or mechanical delay 15, 16 may achieve optimal resynchronization, thereby influencing patient response. However several reports have indicated that there is considerable variability in the ventricular activation pattern and distribution of mechanical dyssynchrony even in the LBBB patient 17 and consequently interindividual variability in the most optimal pacing site. 13, 18 Importantly, a significant percentage of patients do not have the typical LBBB morphology indicating a more heterogeneous activation sequence; consequently, the most effective LV pacing site to restore LV synchrony becomes even more unpredictable. Other published reports have indicated that LV pacing along the lateral or posterolateral wall in patients with ischemic cardiomyopathy and transmural scars in this area may actually limit benefit from CRT. 19 Furthermore, the presence of scar may add to the heterogeneity of the ventricular activation pattern. 20 Although the cause of HF did not significantly affect our results, we did not specifically evaluate the interaction between scar and LV lead location on clinical outcome. In addition, there may be variances in the spatial conductive properties and electric activation of the ventricular myocardium in nonischemic patients. 20 Because of this level of complexity and interpatient variability in the pattern of electric and mechanical dyssynchrony, it is not surprising that there was a lack of incremental benefit from 1 specific pacing site along the anterior, posterior, or lateral wall.
Our results are supported by a retrospective analysis from the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) study suggesting a similar benefit among anterior, lateral, and posterior LV lead locations. 21 This work, however, did not examine the impact of LV lead location between apical and nonapical locations. In addition, there were inherent methodological limitations because the analysis in the COMPANION study was based on LV lead location from investigator reports with no core laboratory validation or use of either venous angiograms or chest x-rays. In contrast to our study, the nomenclature of the pacing site and venous anatomy used in the COMPANION study was less precise and did not detail the different myocardial segments. 21 The most important result of this study is the detrimental effect of LV apical pacing. There are several potential explanations for this finding. First, the LV depolarization wave front in most conduction disturbances activates the apex relatively early during the course of the activation sequence, with the most delayed activation usually occurring along the basal regions of the heart. 14 Hence, an apically positioned LV lead results in pacing a region of the heart with less delayed electric and mechanical activation. Second, CRT involves synchronizing the ventricles via electric stimulation from RV and LV pacing sites that should ideally be positioned as far away from each other as possible. 22 An apically positioned LV lead is in close proximity to an RV lead, which is usually positioned in the RV apex, and would be associated with reduced interelectrode distance and interlead electric separation. In addition, previous studies have demonstrated the harmful effect of RV apical pacing alone, 23 and LV apical pacing with its proximity to the RV apex may have electromechanical effects and a clinical impact similar to worsening HF. Our results are supported by a recent report from a single-center retrospective analysis. 11 Our findings have several important clinical implications pertinent to lead implantation and CRT response. LV lead implantation is limited by constraints of the venous anatomy, phrenic nerve pacing, lead stability, and pacing threshold. Most implanting physicians battle these impediments and struggle, often unsuccessfully, to place the lead along the posterolateral and lateral walls. In situations when a suitable LV lead location cannot be targeted, many implanting centers refer patients for a limited thoracotomy and surgical implantation of an epicardial LV lead. In such circumstances, transvenously placing the LV lead in a nonapical position along the anterior or posterior wall may be a reasonable exit strategy with demonstrable CRT benefit. In addition, in an attempt to ensure the stability of the LV lead, it commonly is pushed out maximally into the apical region. Our results demonstrate that this approach should be avoided as much as possible because apical positions are associated with worse clinical outcomes. It is possible that avoiding the apical region could enhance the overall response to CRT therapy, making this an even more cost-effective strategy.
Conclusions
Appropriate LV lead placement is an important determinant of the success and functional benefit of CRT. The benefit from CRT was similar for LV leads positioned along the anterior, lateral, or posterior wall. LV leads positioned in the apical region were associated with an unfavorable clinical outcome, suggesting that this lead location should be avoided in CRT.
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